Effect of imatinib on plasma glucose concentration in subjects with chronic myeloid leukemia and gastrointestinal stromal tumor

Autor: Diego Molina-Botello, Alejandro Zentella-Dehesa, Álvaro Aguayo-González, Fernando Villanueva-Martinez, Miguel Ángel Gómez-Sámano, Jose Alonso Avila-Rojo, Francisco J. Gómez-Pérez, Melissa Fabiola Coronel Coronel, Lucía Palacios-Báez, Buileng Daniela Wong-Campoverde, Daniel Cuevas-Ramos, Alfonso Gulias-Herrero, Jorge Enrique Baquerizo-Burgos
Rok vydání: 2017
Předmět:
0301 basic medicine
Adult
Blood Glucose
Male
medicine.medical_specialty
medicine.drug_class
Gastrointestinal Stromal Tumors
Endocrinology
Diabetes and Metabolism
Antineoplastic Agents
lcsh:Diseases of the endocrine glands. Clinical endocrinology
Tyrosine-kinase inhibitor
Cohort Studies
03 medical and health sciences
Young Adult
0302 clinical medicine
Internal medicine
Diabetes mellitus
Leukemia
Myelogenous
Chronic
BCR-ABL Positive
Type 2 diabetes mellitus
Medicine
Humans
Retrospective Studies
lcsh:RC648-665
business.industry
Chronic myeloid leukemia
Type 2 Diabetes Mellitus
Myeloid leukemia
Imatinib
General Medicine
Fasting
Middle Aged
medicine.disease
Impaired fasting glucose
Fasting plasma glucose concentrations
030104 developmental biology
Endocrinology
Imatinib mesylate
Treatment Outcome
Diabetes Mellitus
Type 2
030220 oncology & carcinogenesis
Imatinib Mesylate
Female
Gastrointestinal stromal tumor
business
Tyrosine kinase
medicine.drug
Research Article
Zdroj: BMC Endocrine Disorders
BMC Endocrine Disorders, Vol 18, Iss 1, Pp 1-8 (2018)
ISSN: 1472-6823
Popis: Background Type 2 diabetes mellitus has become one of the most important public health concerns worldwide. Due to its high prevalence and morbidity, there is an avid necessity to find new therapies that slow the progression and promote the regression of the disease. Imatinib mesylate is a tyrosine kinase inhibitor that binds to the Abelson tyrosine kinase and related proteins. It enhances β-cell survival in response to toxins and pro-inflammatory cytokine. The aim of this study is to evaluate the effect of imatinib on fasting plasma glucose in subjects with normal fasting glucose, subjects with impaired fasting glucose and in subjects with type 2 diabetes mellitus. Methods We identified 284 subjects diagnosed with chronic myeloid leukemia or gastrointestinal stromal tumors from the Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran database. 106/284 subjects were treated with imatinib. We compared the effect of imatinib on fasting plasma glucose after 1 and 6 months of treatment. We used ANOVA test of repeated samples to determine statistical significance in fasting plasma glucose before imatinib treatment and the follow-up. Statistical analysis was performed with Statistical Package for the Social Sciences v22. Results We included a total of 106 subjects: 76 with fasting plasma glucose concentrations
Databáze: OpenAIRE
Externí odkaz: